Oslo, Norway, 11 August 2022
Vistin Pharma ASA will release its second quarter and YTD 2022 results on Friday 19th of August 2022. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Friday 19th of August at 08:30 CET. There will be a Q&A session following the management discussion.
The conference call will be held in English.
The second quarter conference call will be available via webcast and audio through the following access points:
Webcast:
https://edge.media-server.com/mmc/p/m83myj4s
Telephone conference (online registration):
https://register.vevent.com/register/BI3e5ac1165d974dacab56dd8f81b4fba4
*****
For further information, please contact:
Alexander Karlsen
CFO
+47 97053621
alexander.karlsen@vistin.com
About Vistin Pharma | www.vistin.com
Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well–positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…
Independent report examines Calm Nature CBD Gummies full spectrum formulation, CO2 extraction claims, THC removal…